Rinne, Juha O., Frantzen, Janek, Leinonen, Ville, Lonnrot, Kimmo, Laakso, Aki, Virtanen, Kirsi A., Solin, Olof, Kotkansalo, Anna, Koivisto, Anne, Sajanti, Juha, Karppinen, Atte, Lehto, Hanna, Rummukainen, Jaana, Buckley, Chris, Smith, Adrian, Jones, Paul A., Sherwin, Paul, Farrar, Gill, McLain, Richard, Kailajarvi, Marita, Grachev, Igor D.

Unlabelled: BACKGOUND/OBJECTIVE: To determine the level of association between uptake of the amyloid positron emission tomography (PET) imaging agent [(18)F]flutemetamol and the level of amyloid-β measured by immunohistochemical and histochemical staining in a frontal cortical region biopsy site.; Methods: Seventeen patients with probable normal pressure hydrocephalus (NPH) underwent prospective [(18)F]flutemetamol PET and subsequent frontal cortical […]

Paganini, M., Biggeri, A., Romoli, A. M., Mechi, C., Ghelli, E., Berti, V., Pradella, S., Bucciantini, S., Catelan, D., Saccardi, R., Lombardini, L., Mascalchi, M., Massacesi, L., Porfirio, B., Di Lorenzo, N., Vannelli, G. B., Gallina, P.

Objective: To assess the clinical effect of caudate-putaminal transplantation of fetal striatal tissue in Huntington’s disease (HD).; Methods: We carried out a follow-up study on 10 HD transplanted patients and 16 HD not-transplanted patients. All patients were evaluated with the Unified HD Rating Scale (UHDRS) whose change in motor, cognitive, behavioural and functional capacity total […]

Ossenkoppele, Rik, Prins, Niels D., Pijnenburg, Yolande A.L., Lemstra, Afina W., van der Flier, Wiesje M., Adriaanse, Sofie F., Windhorst, Albert D., Handels, Ron L.H., Wolfs, Claire A.G., Aalten, Pauline, Verhey, Frans R.J., Verbeek, Marcel M., van Buchem, Mark A., Hoekstra, Otto S., Lammertsma, Adriaan A., Scheltens, Philip, van Berckel, Bart N.M.

Background: [(11)C]Pittsburgh compound B ([(11)C]PIB) and [(18)F]-2-fluoro-2-deoxy-D-glucose ([(18)F]FDG) PET measure fibrillar amyloid-β load and glucose metabolism, respectively. We evaluated the impact of these tracers on the diagnostic process in a memory clinic population.; Methods: One hundred fifty-four patients underwent paired dynamic [(11)C]PIB and static [(18)F]FDG PET scans shortly after completing a standard dementia screening. Two-year […]

O'Brien, J. T., Firbank, M. J., Davison, C., Barnett, N., Bamford, C., Donaldson, C., Olsen, K., Herholz, K., Williams, D., Lloyd, J.

Unlabelled: Brain imaging with glucose ((18)F-FDG) PET or blood flow (hexamethylpropyleneamine oxime) SPECT is widely used for the differential diagnosis of dementia, though direct comparisons to clearly establish superiority of one method have not been undertaken.; Methods: Subjects with Alzheimer disease (AD; n = 38) and dementia with Lewy bodies (DLB; n = 30) and […]

Miyoshi, F., Ogawa, T., Kitao, S.- i., Kitayama, M., Shinohara, Y., Takasugi, M., Fujii, S., Kaminou, T.

Background and Purpose: Progressive changes in the substantia nigra pars compacta and locus ceruleus of patients with Parkinson disease and Alzheimer disease visualized by neuromelanin MRI and cardiac postganglionic sympathetic nerve function on (123)I-metaiodobenzylguanidine scintigraphy have not been fully evaluated. We compared the diagnostic value of these modalities among patients with early Parkinson disease, late […]

Mathis, Chester A., Kuller, Lewis H., Klunk, William E., Snitz, Beth E., Price, Julie C., Weissfeld, Lisa A., Rosario, Bedda L., Lopresti, Brian J., Saxton, Judith A., Aizenstein, Howard J., McDade, Eric M., Kamboh, M. Ilyas, DeKosky, Steven T., Lopez, Oscar L.

Objective: This study examined amyloid-β (Aβ) deposition in 190 nondemented subjects aged ≥82 years to determine the proportion of Aβ-positive scans and associations with cognition, apolipoprotein E (APOE) status, brain volume, and Ginkgo biloba (Gb) treatment.; Methods: Subjects who agreed to participate had a brain magnetic resonance imaging and positron emission tomography scan with (11) […]

Grundman, Michael, Pontecorvo, Michael J., Salloway, Stephen P., Doraiswamy, P. Murali, Fleisher, Adam S., Sadowsky, Carl H., Nair, Anil K., Siderowf, Andrew, Lu, Ming, Arora, Anupa K., Agbulos, Abigail, Flitter, Matthew L., Krautkramer, Michael J., Sarsour, Khaled, Skovronsky, Daniel M., Mintun, Mark A.

Florbetapir F18 has been approved by the Food and Drug Administration for in vivo assessment of amyloid pathology in patients undergoing evaluation for Alzheimer disease (AD). The aim of this study was to determine the impact of amyloid imaging on the diagnoses and management of patients undergoing evaluation for cognitive decline. Patients were recruited to […]

Buerger, Katharina, Frisoni, Giovanni, Uspenskaya, Olga, Ewers, Michael, Zetterberg, Henrik, Geroldi, Cristina, Binetti, Giuliano, Johannsen, Peter, Rossini, Paolo Maria, Wahlund, Lars-Olof, Vellas, Bruno, Blennow, Kaj, Hampel, Harald

Background: Alzheimer’s Disease Neuroimaging Initiatives (“ADNI”) aim to validate neuroimaging and biochemical markers of Alzheimer’s disease (AD). Data of the pilot European-ADNI (E-ADNI) biological marker programme of cerebrospinal fluid (CSF) and plasma candidate biomarkers are reported.; Methods: Six academic EADC centres recruited 49 subjects (healthy controls, subjects with mild cognitive impairment (MCI) and AD). We […]

Bahar-Fuchs, Alex, Villemagne, Victor, Ong, Kevin, Chetélat, Gaël, Lamb, Fiona, Reininger, Cornelia B., Woodward, Michael, Rowe, Christopher C.

Assessment of disease biomarkers, particularly the in vivo assessment of amyloid-β (Aβ) burden with positron emission tomography (PET), is gradually becoming central to the diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD). However, the incorporation of biomarker evidence to the diagnostic process is currently restricted mainly to research settings. The identification of […]